Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAF312A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAF312A (2 doses in part B; 5 - 6 doses in part C) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Ibuprofen | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SAF312A | DRUG | - |
| Placebo | DRUG | - |
| Ibuprofen | DRUG | - |
Inclusion Criteria: * Extraction of two or more impacted (partial or full) third molars. At least one of the impaction should be lower jaw. * Each patient will evaluate her/his post-surgical pain intensity prior to taking trial medication. * To be eligible for this trial, post surgical pain must be...
SAF312A is an investigational small molecule being developed for the treatment of postoperative pain. It is currently in Phase 2 clinical development, with a completed trial evaluating its safety, tolerability, and analgesic efficacy in patients with postoperative dental pain.
SAF312A is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company conducted a Phase 2 clinical trial of SAF312A in the United States.
SAF312A is in Phase 2 clinical development for postoperative pain. It is an investigational drug, not yet approved by regulatory authorities. One Phase 2 trial has been completed, involving 183 participants, and no active trials are currently listed.
SAF312A has one completed clinical trial registered as NCT00986882, titled "To Evaluate the Safety, Tolerability and Analgesic Efficacy of SAF312 in Postoperative Dental Pain Patients." This Phase 2, randomized, double-blind, placebo-controlled study enrolled 183 adults in the United States.
Yes, SAF312A is the same compound as SAF312. The clinical trial NCT00986882 refers to the drug as SAF312, while the drug name SAF312A is used in development records. Both names refer to the same investigational small molecule for postoperative pain.